Paul Goodard of Neurex Corp. in Menlo Park, Calif., was misidentifiedin Thursday's edition of BioWorld Today. He is the company's chiefexecutive officer.In an article on DDI Inc. in Thursday's issue, BioWorld Today wasmistakenly informed that the Italian government had banned the sale ofDDI's product, orgotein, the generic form of bovine superoxidedismutase. In fact, Italian authorities decided not to providereimbursement for purchase of the product _ sold in Italy as Oxynorm_ but did not ban it.
(c) 1997 American Health Consultants. All rights reserved.